Teva To Bring First Biosimilar For Lucentis In The UK - Quick Facts

Teva Pharmaceutical Industries Ltd (TEVA) announced the UK Medicines & Healthcare Regulatory Agency has decided to grant a licence for Ongavia, a biosimilar to Lucentis (ranibizumab), an eye injection. The United Kingdom is the first country in Europe to authorize commercialization of Ongavia for the treatment of neovascular (wet)
age-related macular degeneration.

Teva entered into a strategic partnership for the exclusive commercialisation of ranibizumab with Bioeq AG. The company hopes to commercialise the ranibizumab biosimilar across Europe.

Lucentis is a registered trademark of Genentech Inc.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Ice Cream maker Ben & Jerry's reportedly filed a lawsuit against parent and British consumer giant Unilever to stop the sale of its Israeli business to a local license-holder Avi Zinger. The company alleged that the decision was made without the approval of its independent board. The judge reportedly denied Ben & Jerry's application for a temporary restraining order against Unilever. J&M Foods is recalling certain Lavender Shortbread Cookies sold through department store chain Target Corp. due to undeclared allergens, the U.S. Food and Drug Administration said. These packages were erroneously packed with Chocolate Chip Cookies and do not disclose the presence of a possible allergen, such as soy or eggs. A multi-state listeria outbreak that has killed one and sickened at least 23 others has been linked to Florida -based Big Olaf Creamery brand ice cream, according to the Centers for Disease Control and Prevention or CDC. The outbreak strain has been reported from 10 states, resulting in 22 hospitalizations. One death has been reported from Illinois.
Follow RTT